Joel leads the Computational Biology and Bioinformatics group at Life Edit Therapeutics. He has more than 20 years of experience in design, operations, and analysis of large scale genetic and genomic experiments.
Prior to joining Life Edit, Joel led the Lineberger Bioinformatics Shared Resource at University of North Carolina and was an Associate Professor in the Department of Genetics, where he remains an Adjunct Associate Professor. Joel’s Ph.D. efforts under Chuck Perou and continuing work with Nanostring resulted in Prosigna, the first FDA-approved IVDMIA with indications in breast cancer. He also co-developed RNA-sequencing programs at Expression Analysis (now Q2 Solutions) for The Cancer Genome Atlas. He subsequently co-founded Select Immunogenomics, which was acquired by GeneCentric in 2019. His broad scientific collaborations encompass >250 peer-reviewed manuscripts with an h-index > 100.
Joel received his Ph.D. in Bioinformatics and Computational Biology from the University of North Carolina and holds an M.S. in Biomedical Informatics from Vanderbilt University. He also received his B.S. in Biology and Computer Science from the University of Tennessee.
